CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

This study is testing whether a combination of two oral drugs, zanubrutinib and venetoclax, can effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after at least one prior treatment. The main goal is to see if t…

This study is testing whether giving the same two-drug combination again can help control chronic lymphocytic leukemia (CLL) when it returns after previous treatment. The trial will enroll about 75 adults whose CLL came back more than 12 months after they finished their first tre…

This is an early-stage study testing the safety and initial effectiveness of a new drug combination called UB-VV111 plus rapamycin. It is for adults with certain advanced B-cell blood cancers (like lymphoma and leukemia) that have come back or stopped responding to other treatmen…

This early-phase study is testing a new cell therapy called GT801 in adults with advanced blood cancers or autoimmune anemia that has not responded to standard treatments. The main goals are to check if the treatment is safe and to see early signs of whether it helps control the …

This study is testing an experimental oral drug called NX-5948 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to standard treatments. The drug works differently than previous medications by completely…

This study is testing whether the drug venetoclax can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults whose cancer has come back or stopped responding to other treatments. It is specifically for people who have already tried certain o…

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This study is observing how well the drug venetoclax works for people with chronic lymphocytic leukemia (CLL) in real-world clinic settings. It will follow 500 patients in Austria, Germany, and Switzerland who are prescribed this medication, either alone or in combination with ot…

This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—for people with untreated CLL or SLL. The main goal is to see how many patients achieve a deep response where no cancer cells can be detected in their blood or bone marrow. It aims to co…

This program provides early access to the drug venetoclax for patients with certain blood cancers like leukemia and lymphoma before it is fully approved in their country. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trial…

This study aims to understand how daily life, fatigue, and symptoms change over two years for adults receiving treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma. Researchers will follow 100 patients who are starting specific cancer medications, tracking the…

This study is creating a national registry to track how nearly 3000 people in Germany with various blood cancers are treated in real-world settings. It will document what treatments patients receive, how they respond, and how their quality of life is affected over time. The goal …

This study aims to collect blood, urine, and tissue samples from adults with certain blood cancers and from healthy volunteers. The goal is to study these samples in a lab to better understand diseases like hairy cell leukemia and to help develop future treatments. No treatment i…

This study is collecting information on how well the drug acalabrutinib works for patients with chronic lymphocytic leukemia (CLL) in real-world UK clinics. It will look back at the medical records of about 350 adults who started this treatment through a special early access prog…

This study aims to understand how the drug pirtobrutinib affects the immune system when used as a first treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers will enroll about 30 adults with untreated CLL or SLL to take the drug daily a…

This study aims to understand how certain leukemia and lymphoma drugs, called BTK inhibitors, affect the heart and may increase the risk of dangerous irregular heartbeats. Researchers will monitor 135 adults who are already taking or planning to start these drugs, using heart tes…